Ipca Laboratories approves merger with Krebs Biochemicals
after close1 source ↓written by the desknot a recommendation
- effective
- 1 Apr 2026
- board decision
- 26 Jun 2026
- total income
- ₹7,431 cr
- while Krebs reported
- ₹26 cr
Ipca Laboratories has approved the amalgamation with Krebs Biochemicals to enhance the supply of critical fermentation-based Active Pharmaceutical Ingredients (APIs). The merger, effective from 1 Apr 2026, follows a board decision on 26 Jun 2026. For FY 2026, Ipca reported total income of ₹7,431 cr, while Krebs reported ₹26 cr.
This merger may strengthen Ipca's position in the pharmaceutical sector, potentially impacting market dynamics and supply chains.
Not investment advice. For informational purposes only.